ANDA 211045, held by Alicora. Darifenacin Hydrobromide.
As of Nov 16, 2026, ANDA 211045 (Darifenacin Hydrobromide), held by Alicora, was first approved by FDA on Jan 6, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 6, 2020 | Original application | Approved | None posted |
| Darifenacin HydrobromideEQ 7.5MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
| Darifenacin HydrobromideEQ 15MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters